The National Institute for Health and Care Excellence (NICE) has recommended Sogroya (somapacitan injection) for children aged 3 to 17 years with paediatric growth hormone deficiency.
The once-weekly treatment, developed by Novo Nordisk, offers an alternative to existing therapies for children experiencing growth failure due to the condition.
Growth hormone deficiency affects an estimated 1 in 3,500-4,000 children in the UK, where their bodies do not produce enough of the hormone naturally. Growth hormone, produced by the pituitary gland, is essential for normal growth during childhood.
Sogroya acts as a replacement for endogenous growth hormone and is administered once a week to support growth in children with the condition. NICE’s recommendation provides families and healthcare providers with another treatment option for managing paediatric growth hormone deficiency.
Sebnem Avsar Tuna, General Manager of Novo Nordisk UK, welcomed the decision: “We believe the launch of Sogroya will help provide an additional option to support people living with growth hormone deficiencies in the UK and look forward to working with healthcare providers to achieve this.”
Novo Nordisk has developed Sogroya as a treatment for both paediatric and adult growth hormone deficiency. The therapy is intended for children aged 3 years and older who experience growth failure due to inadequate hormone production.
With NICE’s recommendation, healthcare providers will now have access to an additional therapy to support children affected by this condition.
